Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that can cause cancer—that may ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

The drug pipeline—the process through which a potential new drug gets discovered, tested, approved, and marketed—is a ...

Travere Therapeutics today announced that the Company will present three abstracts at the upcoming International Podocyte Conference.

Hong went on to coauthor an article published in the New England Journal of Medicine that described findings from phase 1/2 studies of the TRK inhibitor larotrectinib (Vitrakvi). 6 The FDA approved ...

COX-2 inhibitors, also known as selective COX-2 inhibitors, are nonsteroidal anti-inflammatory drugs (NSAIDs) that treat inflammatory pain. They’re available by prescription and may be easier on ...

Cyclooxygenase-2 is overexpressed in bladder cancer cells, making it an attractive molecular target for the detection and treatment of cancer.

Preclinical studies suggest it may be possible to use a combination of approved cyclooxygenase-2 (COX-2) inhibitors and anti-programmed cell death 1 (anti-PD1) immune checkpoint inhibitors to ...

The adjusted hazard ratio (HR) for death from ischemic stroke was 1.19 for current users of selective COX-2 inhibitors compared with nonusers. This was driven by the effect among new users (HR, 1.42).